In a development that has reignited debates about drug policy on both sides of the Atlantic, the assistant to late actor Matthew Perry has been sentenced to 18 months in federal prison for supplying the ketamine that contributed to his death. But for UK drug reform campaigners, the case is less about individual culpability and more about a broader systemic failure that prioritises punishment over public health.
Perry, the beloved star of ‘Friends’, died in October 2023 from acute effects of ketamine, a drug that, in controlled settings, has shown promise for treating depression and anxiety. His assistant, who prosecutors accused of administering multiple injections without medical supervision, now faces a lengthy prison term.
Yet voices from the UK’s drug policy reform community argue that the tragedy exposes a deeper issue: the criminalisation of drug use drives such behaviour underground, preventing harm reduction and fostering dangerous, unregulated supply chains.
“Ketamine-assisted therapy is not a fringe experiment; it’s a clinically validated treatment in many jurisdictions,” says Dr. Julian Vane, our Technology and Innovation Lead and a former Silicon Valley ethicist turned policy analyst. “We have a bizarre paradox where a drug responsible for countless clinical breakthroughs is simultaneously causing deaths because of its uncontrolled, illegal diversion. The real systemic failure is that we treat addiction as a moral failing instead of a medical condition.”
The UK’s own record on drug-related deaths is grim. According to the Office for National Statistics, deaths from drug misuse reached a record high in 2023, with ketamine fatalities among young adults rising sharply. Campaigners point to Portugal’s decriminalisation model, which saw addiction rates plummet after treating drug use as a health issue.
“We follow the American zero-tolerance playbook even as it fails,” notes Vane. “Meanwhile, technology offers unprecedented transparency: blockchain tracking for pharmaceuticals, AI-driven telehealth for addiction, digital tools for monitoring adverse reactions. But we use none of it because our laws are frozen in the Reagan era.”
The assistant’s sentencing has also prompted debate about accountability in an era of DIY therapy, where online influencers tout psychedelics as panaceas without medical oversight. “The internet has democratised access but removed safeguards,” Vane observes. “It’s a classic Black Mirror scenario: we have the most powerful tools for healing and destruction coexisting in an unregulated digital ecosystem.”
UK-based drug reform group Transform has called for a parliamentary inquiry into how regulatory gaps allow dangerous practices to flourish. “Every celebrity overdose is framed as an individual tragedy, but it’s a canary in the coal mine for a broken system,” said a spokesperson.
As Perry’s assistant prepares for prison, the conversation is moving from blame to prevention. Vane synthesises the tension: “We need to separate the urgent need for accountability from the equally urgent need for policy evolution. The sentence may satisfy a thirst for justice, but it does nothing to stop the next tragedy. If we want to honour Matthew Perry’s memory, let’s build a system that treats addiction as a disease, not a crime, and leverage every technological tool to make drug use safer, not just rarer.”
For now, the UK watches a case that echoes its own struggles: a war on drugs that has failed to stem the tide of deaths, leaving families and advocates asking whether the next headline will be a cautionary tale or a catalyst for change.
